Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders

Rhea-AI Summary

Damora Therapeutics (NASDAQ:DMRA) announced its name change from Galecto effective March 10, 2026, following completion of the acquisition of Damora and a concurrent private investment of approximately $285 million in November 2025.

The company reported approximately $535 million in cash and cash equivalents as of February 28, 2026, and gross proceeds of about $316 million from a February 2026 public offering. Damora plans IND/CTA submissions for lead program DMR-001 in mid-2026, additional IND/CTAs for DMR-002 (H2 2026) and DMR-003 (2027), and expects two clinical proof-of-concept datasets for DMR-001 beginning mid-2027. The pipeline targets mutCALR-driven ET and MF, affecting an estimated ~42,000 US patients.

Positive

• Trading symbol changes to DMRA effective March 10, 2026
• Approximately $535 million cash and cash equivalents as of February 28, 2026
• Concurrent financing: ~$285 million private investment (Nov 2025) and ~$316 million gross public offering (Feb 2026)
• On track to submit IND/CTA for DMR-001 in mid-2026
• Two clinical proof-of-concept datasets for DMR-001 expected beginning mid-2027

Negative

• Lead program DMR-001 remains at preclinical stage; clinical proof-of-concept not expected until mid-2027
• Regulatory submissions are pending (IND/CTA planned mid-2026), so clinical start and approvals are uncertain

News Market Reaction – GLTO

-0.76%

6 alerts

-0.76% News Effect

-12.1% Trough in 3 hr 26 min

-$14M Valuation Impact

$1.81B Market Cap

0.3x Rel. Volume

On the day this news was published, GLTO declined 0.76%, reflecting a mild negative market reaction. Argus tracked a trough of -12.1% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $14M from the company's valuation, bringing the market cap to $1.81B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cash and equivalents: $535 million Private investment: $285 million Public offering proceeds: $316 million +5 more

8 metrics

Cash and equivalents $535 million As of February 28, 2026; expected runway into Phase 3 DMR-001

Private investment $285 million Concurrent private investment in November 2025

Public offering proceeds $316 million Gross proceeds from recent public offering in February 2026

mutCALR ET share 25% Proportion of ET cases driven by mutCALR

mutCALR MF share 35% Proportion of MF cases driven by mutCALR

Patient population 42,000 patients Estimated U.S. patients with mutCALR-driven MPNs

Proof-of-concept datasets 2 datasets DMR-001 clinical proof-of-concept datasets expected beginning mid-2027

DMR-001 IND/CTA timing Mid-2026 Planned IND or CTA submission for DMR-001 in ET and MF

Market Reality Check

Price: $28.69 Vol: Volume 116,925 shares is ...

low vol

$28.69 Last Close

Volume Volume 116,925 shares is below the 20-day average of 415,510, suggesting no outsized positioning ahead of this news. low

Technical Shares at $28.82 are trading above the 200-day moving average of $12.87, after a large recovery from the 52-week low of $2.01 and still below the 52-week high of $38.33.

Peers on Argus

GLTO gained 1.94% with mixed peer moves: QLGN and SLXN rose (7.72%, 4.85%), whil...

GLTO gained 1.94% with mixed peer moves: QLGN and SLXN rose (7.72%, 4.85%), while ENTO and BDRX fell (-5.68%, -4.37%) and TOVX was roughly flat. No peers appeared in the momentum scanner, pointing to a stock-specific catalyst.

Historical Context

5 past events · Latest: Mar 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	Inducement option grants	Neutral	+5.7%	Inducement stock options for new hires under Nasdaq Listing Rule 5635(c)(4).
Mar 02	Conference participation	Neutral	+1.6%	Participation in Leerink Partners 2026 Global Healthcare Conference fireside chat.
Feb 12	Offering closing	Negative	-3.0%	Closing of public offering with full over-allotment, raising about $316.3M.
Feb 10	Offering pricing	Negative	+1.3%	Pricing of $275M underwritten equity offering at $19.00 per share.
Feb 10	Offering proposal	Negative	+1.3%	Proposed offering of common and Series C preferred stock for R&D funding.

Pattern Detected

Equity offerings have drawn mixed reactions, while routine corporate updates have generally seen modest positive moves.

Recent Company History

Over the past month, Galecto has focused on financing and corporate housekeeping ahead of its hematology pivot. In February 2026, it announced, priced, and then closed a sizable underwritten offering tied to an automatic shelf, with proceeds earmarked for antibody programs including DMR-001. Subsequent news in early March 2026 covered a conference appearance and inducement option grants. Today’s rebranding to Damora Therapeutics and emphasis on mutCALR programs and cash runway into Phase 3 build directly on those capital-raising and strategic shift disclosures.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-10

An automatic shelf registration on Form S-3ASR filed on February 10, 2026 allows Galecto to issue common stock, preferred stock, debt securities, warrants and units using prospectus supplements. The shelf is effective and has already been used in at least two offerings, providing flexibility for additional capital raises that could impact existing shareholders.

Market Pulse Summary

This announcement highlights Galecto’s transition to Damora Therapeutics, a focused strategy around ...

Analysis

This announcement highlights Galecto’s transition to Damora Therapeutics, a focused strategy around mutCALR-driven myeloproliferative neoplasms, and a reported cash position of $535 million supporting development of DMR-001 into Phase 3. The company lays out clear milestones for IND or CTA submissions across DMR-001, DMR-002 and DMR-003 through 2027, and plans two proof-of-concept datasets starting mid-2027. Investors may watch execution against these timelines and any further use of the existing shelf registration.

Key Terms

investigational new drug (IND) application, clinical trial application (CTA), monoclonal antibody, subcutaneous, +2 more

6 terms

investigational new drug (IND) application regulatory

"Submit an investigational new drug (IND) application to the U.S. Food and Drug"

An investigational new drug (IND) application is a formal request submitted to a drug regulator asking permission to begin testing a new medicine in people. It compiles lab results, manufacturing details and proposed human trial plans so regulators can judge safety before human studies start; for investors, an accepted IND is a key milestone that opens the clinical development pathway and can materially change a company’s risk profile and potential value, like getting a license to road-test a prototype.

clinical trial application (CTA) regulatory

"IND or CTA to a regulatory authority in another country for DMR-001"

A clinical trial application (CTA) is the formal request a company files with health regulators asking permission to begin testing a new drug or medical device in people. It matters to investors because approval is a key development milestone—like getting a building permit to start construction—signaling reduced regulatory risk, unlocking the next phase of data generation and timelines for potential commercial value, while rejection or delay can push back prospects and increase costs.

monoclonal antibody medical

"DMR-001 is an investigational monoclonal antibody therapy targeting mutCALR"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

subcutaneous medical

"extended half-life expected to enable convenient, infrequent subcutaneous dosing"

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

myeloproliferative neoplasms (MPNs) medical

"mutCALR-driven myeloproliferative neoplasms (MPNs), where there is high medical need"

Myeloproliferative neoplasms (MPNs) are a group of chronic blood cancers in which the bone marrow makes too many blood cells, upsetting normal circulation and causing symptoms such as fatigue, bruising, clotting or organ enlargement. They matter to investors because treatments are usually long-term and many patients lack fully effective therapies, so successful drugs, diagnostics or regulatory approvals can produce steady revenues or sharply change a company's value—like winning a durable, niche market where clinical and safety results drive investor decisions.

mutant calreticulin (mutCALR) medical

"mutant calreticulin (mutCALR)-targeted therapeutics in essential thrombocythemia"

Mutant calreticulin (mutCALR) is an altered form of the calreticulin protein caused by specific genetic changes; it is found in certain blood cancers where it helps drive abnormal blood cell growth. For investors, mutCALR matters because it serves as a diagnostic marker and a target for drugs—think of it like a misprinted recipe that both reveals what went wrong in the kitchen and points to how a new ingredient (a therapy) might fix the dish, affecting market value for diagnostics and treatments.

AI-generated analysis. Not financial advice.

-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 --

-- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in mid-2026, with two clinical proof-of-concept datasets expected mid-2027 --

-- Strong financial position with approximately $535 million of cash and cash equivalents as of February 28, 2026, with anticipated runway into Phase 3 development of DMR-001 --

BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (Galecto or the Company) (NASDAQ: GLTO), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its name change to Damora Therapeutics, Inc. (Damora). Effective March 10, 2026, Damora will trade on Nasdaq under the trading symbol “DMRA.”

The name change follows the completion of Galecto’s previously announced acquisition of privately held Damora and a concurrent private investment of approximately $285 million in November 2025. Combined with gross proceeds of approximately $316 million from the Company’s recently closed public offering in February 2026, Damora plans to rapidly advance its pipeline of mutant calreticulin (mutCALR)-targeted therapeutics in essential thrombocythemia (ET) and myelofibrosis (MF), beginning with lead program DMR-001.

“As Damora Therapeutics, we are bringing innovative, disease-modifying medicines to patients with mutCALR-driven myeloproliferative neoplasms (MPNs), where there is high medical need and no available treatments that target the underlying cause of disease,” said Sherwin Sattarzadeh, Chief Operating Officer. “With a strong operational foundation including board and executive leadership with a track record of clinical and commercial success, we are now scaling efforts to initiate clinical development of DMR-001 and rapidly advance it toward registration.”

DMR-001 is an investigational monoclonal antibody therapy targeting mutCALR with best-in-class potential, demonstrated by preclinical data showing its potent inhibition of both Type 1 and Type 2 mutCALR and an extended half-life expected to enable convenient, infrequent subcutaneous dosing. The Company’s additional anti-mutCALR pipeline therapies, DMR-002 and DMR-003, enable portfolio optionality to address the full spectrum of patients with mutCALR-driven MPNs.

MPNs are a group of rare, chronic blood cancers characterized by the abnormal production of blood cells in the bone marrow. MutCALR drives uncontrolled proliferation and disease progression in 25 percent of ET and 35 percent of MF cases. There are approximately 42,000 patients in the United States living with mutCALR-driven MPNs.

Damora anticipates the following upcoming milestones across its mutCALR programs:

• Submit an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) or a clinical trial application (CTA) to a regulatory authority in another country for DMR-001 in mid-2026
• Submit an IND or CTA for DMR-002 in the second half of 2026
• Submit an IND or CTA for DMR-003 in 2027
• Present two clinical proof-of-concept datasets for DMR-001 beginning mid-2027
  
  

About Damora Therapeutics
Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.

Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to the Company’s expectations, hopes, beliefs, intentions or strategies regarding the future of its assets, pipeline and business including, without limitation, the timing for IND or CTA submissions for DMR-001, DMR-002 and DMR-003, the expected method of administration for DMR-001, the expected timing for Phase 1 data for DMR-001 and the length of time that the Company believes its existing cash and cash equivalents will fund its operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the Company will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those uncertainties and factors described under the headings “Risk Factors,” “Cautionary Information Regarding Forward-Looking Statements” or “Cautionary Statement Regarding Forward-Looking Statements” in the Company’s most recent filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.

Media Contact:

Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com

Investor Contact:

Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

FAQ

When will Galecto begin trading under the new name Damora Therapeutics (DMRA)?

Damora will begin trading under DMRA on Nasdaq effective March 10, 2026. According to the company, the name change follows completion of the acquisition of Damora and related financing in 2025.

How much cash does Damora Therapeutics (DMRA) have to fund DMR-001 development?

Damora reported approximately $535 million in cash and cash equivalents as of Feb 28, 2026. According to the company, this cash position, plus recent financings, supports advancement toward Phase 3 development of DMR-001.

What are Damora’s near-term clinical milestones for DMR-001 and other programs?

Damora plans to submit an IND or CTA for DMR-001 in mid-2026 and expects two proof-of-concept datasets beginning mid-2027. According to the company, IND/CTA filings for DMR-002 are planned in H2 2026 and for DMR-003 in 2027.

What financing did Damora complete to support its pipeline after the acquisition?

The company closed a private investment of ~$285 million in Nov 2025 and raised ~$316 million gross in a Feb 2026 public offering. According to the company, these financings underpin rapid advancement of mutCALR programs.

How large is the target patient population for Damora’s mutCALR programs (DMR-001, DMR-002, DMR-003)?

Damora estimates approximately 42,000 patients in the U.S. with mutCALR-driven MPNs; mutCALR is present in ~25% of ET and ~35% of MF cases. According to the company, this defines the addressable patient population for its therapies.